References
- Abbasi S, Nouri M, Azimi C (2012). Estrogen receptor genes variations and breast cancer risk in Iran. Int J Clin Exp Med, 5, 332-41.
- Bieche I, Parfait B, Laurendeau I, et al (2001). Quantification of estrogen receptor a and b expression in sporadic breast Cancer. Oncogene, 20, 8109-15. https://doi.org/10.1038/sj.onc.1204917
- Buzdar AU (2013). Meta-analysis: Selective estrogen-receptor modulators reduce breast cancer incidence. Ann Intern Med, 159, 9.
- Clark GM, Sledge GW, Osborne CK, et al (1987). Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol, 5, 55-61.
- Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P, et al (2014). Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. Asian Pac J Cancer Prev, 15, 1187-92. https://doi.org/10.7314/APJCP.2014.15.3.1187
- De Cremoux P, Tran-Perennou C, Elie C, et al (2002). Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction correlation with protein assays. Bichem Pharmacol, 64, 507-15. https://doi.org/10.1016/S0006-2952(02)01187-5
- Gopalan V, Pillai S, Ebrahimi F, et al (2014). Regulation of microRNA-1288 in colorectal cancer: Altered expression and its clinicopathological significance. Mol Carcinog, 53, 36-44. https://doi.org/10.1002/mc.21993
- Gopalan V, Smith RA, Nassiri MR, et al (2010). GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features. Hum Pathol, 41, 1009-15. https://doi.org/10.1016/j.humpath.2009.11.014
- Holst F, Stahl PR, Ruiz C, et al (2007). Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet, 39, 655-60. https://doi.org/10.1038/ng2006
-
Hooshmand S, Ghaderi A, Yusoff K, et al (2014). Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI-
$\alpha$ silencing and overexpression. Asian Pac J Cancer Prev, 15, 3311-7 https://doi.org/10.7314/APJCP.2014.15.7.3311 - Izadi P, Noruzinia M, Karimipoor M, et al (2012). Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. Cell J, 14, 102-9.
- Lam AK, Gopalan V, Nassiri MR, et al (2011). Altered JS-2 expression in colorectal cancers and its clinical pathological relevance. Mol Oncol, 5, 475-81. https://doi.org/10.1016/j.molonc.2011.06.003
- Medina-Jaime AD, Reyes-Vargas F, Martinez-Gaytan V, et al (2014). ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer. Asian Pac J Cancer Prev, 15, 3041-4. https://doi.org/10.7314/APJCP.2014.15.7.3041
- Mousavi SM, Mohagheghi MA, Mousavi-Jerrahi A, et al (2008). Outcome of breast cancer in Iran: a study of Tehran Cancer Registry data. Asian Pac J Cancer Prev, 9, 275-8.
- Nilsson S, Makela S, Treuter E, et al (2001). Mechanisms of estrogen action. Physiol Rev, 81, 1535-65.
- Rahimzadeh M, Baghestani AR, Gohari MR, Pourhoseingholi MA (2014). Estimation of the cure rate in Iranian breast cancer patients. Asian Pac J Cancer Prev, 15, 4839-42. https://doi.org/10.7314/APJCP.2014.15.12.4839
- Wang LW, Yang GF, Chen JM, et al (2014). A clinical database of breast cancer patients reveals distinctive clinico-pathological characteristics: a study from central China. Asian Pac J Cancer Prev, 15, 1621-6. https://doi.org/10.7314/APJCP.2014.15.4.1621